These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 24129068)

  • 1. Cytokine and nitric oxide patterns in dogs immunized with LBSap vaccine, before and after experimental challenge with Leishmania chagasi plus saliva of Lutzomyia longipalpis.
    Resende LA; Roatt BM; Aguiar-Soares RD; Viana KF; Mendonça LZ; Lanna MF; Silveira-Lemos D; Corrêa-Oliveira R; Martins-Filho OA; Fujiwara RT; Carneiro CM; Reis AB; Giunchetti RC
    Vet Parasitol; 2013 Dec; 198(3-4):371-81. PubMed ID: 24129068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after Leishmania chagasi-Challenge.
    Resende LA; Aguiar-Soares RD; Gama-Ker H; Roatt BM; Mendonça LZ; Alves ML; Silveira-Lemos Dd; Corrêa-Oliveira R; Martins-Filho OA; Araújo MS; Fujiwara RT; Gontijo NF; Reis AB; Giunchetti RC
    PLoS One; 2016; 11(8):e0161169. PubMed ID: 27556586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation.
    Roatt BM; Aguiar-Soares RD; Vitoriano-Souza J; Coura-Vital W; Braga SL; Corrêa-Oliveira R; Martins-Filho OA; Teixeira-Carvalho A; de Lana M; Figueiredo Gontijo N; Marques MJ; Giunchetti RC; Reis AB
    PLoS One; 2012; 7(11):e49780. PubMed ID: 23189161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dogs immunized with LBSap vaccine displayed high levels of IL-12 and IL-10 cytokines and CCL4, CCL5 and CXCL8 chemokines in the dermis.
    Vitoriano-Souza J; Moreira Nd; Menezes-Souza D; Roatt BM; de Oliveira Aguiar-Soares RD; Siqueira-Mathias FA; de Oliveira Cardoso JM; Giunchetti RC; de Sá RG; Corrêa-Oliveira R; Carneiro CM; Reis AB
    Mol Immunol; 2013 Dec; 56(4):540-8. PubMed ID: 23911411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis.
    de Mendonça LZ; Resende LA; Lanna MF; Aguiar-Soares RD; Roatt BM; Castro RA; Batista MA; Silveira-Lemos D; Gomes Jde A; Fujiwara RT; Rezende SA; Martins-Filho OA; Corrêa-Oliveira R; Dutra WO; Reis AB; Giunchetti RC
    Parasit Vectors; 2016 Aug; 9(1):472. PubMed ID: 27577735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral blood mononuclear cell supernatants from asymptomatic dogs immunized and experimentally challenged with Leishmania chagasi can stimulate canine macrophages to reduce infection in vitro.
    Rodrigues CA; Batista LF; Teixeira MC; Pereira AM; Santos PO; de Sá Oliveira GG; de Freitas LA; Veras PS
    Vet Parasitol; 2007 Feb; 143(3-4):197-205. PubMed ID: 17045743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell-derived cytokines, nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune.
    Araújo MS; de Andrade RA; Sathler-Avelar R; Teixeira-Carvalho A; Andrade MC; Vianna LR; Mayrink W; Reis AB; Malaquias LC; Mello MN; Martins-Filho OA
    Vaccine; 2009 Feb; 27(7):1008-17. PubMed ID: 19110023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LBSapSal-vaccinated dogs exhibit increased circulating T-lymphocyte subsets (CD4⁺ and CD8⁺) as well as a reduction of parasitism after challenge with Leishmania infantum plus salivary gland of Lutzomyia longipalpis.
    Aguiar-Soares RD; Roatt BM; Ker HG; Moreira Nd; Mathias FA; Cardoso JM; Gontijo NF; Bruna-Romero O; Teixeira-Carvalho A; Martins-Filho OA; Corrêa-Oliveira R; Giunchetti RC; Reis AB
    Parasit Vectors; 2014 Feb; 7():61. PubMed ID: 24507702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoprophylactic Potential of a New Recombinant
    Pessoa-E-Silva R; Trajano-Silva LAM; Vaitkevicius-Antão V; Dos Santos WJT; Magalhães FB; Moura DMN; Nakasone EKN; de Lorena VMB; de Paiva-Cavalcanti M
    Front Immunol; 2020; 11():605044. PubMed ID: 33488607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
    Petitdidier E; Pagniez J; Papierok G; Vincendeau P; Lemesre JL; Bras-Gonçalves R
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004614. PubMed ID: 27223609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs.
    Giunchetti RC; Corrêa-Oliveira R; Martins-Filho OA; Teixeira-Carvalho A; Roatt BM; de Oliveira Aguiar-Soares RD; Coura-Vital W; de Abreu RT; Malaquias LC; Gontijo NF; Brodskyn C; de Oliveira CI; Costa DJ; de Lana M; Reis AB
    Vaccine; 2008 Jan; 26(5):623-38. PubMed ID: 18180079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
    Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
    Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
    Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of cell migration to the dermis and hypodermis in dogs vaccinated with antigenic compounds of Leishmania braziliensis plus saponin.
    Vitoriano-Souza J; Reis AB; Moreira ND; Giunchetti RC; Correa-Oliveira R; Carneiro CM
    Vaccine; 2008 Jul; 26(31):3922-31. PubMed ID: 18555567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis.
    Khare P; Jaiswal AK; Tripathi CD; Sundar S; Dube A
    Clin Exp Immunol; 2016 Aug; 185(2):165-79. PubMed ID: 26898994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
    Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
    Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipophosphoglycan-3 protein from Leishmania infantum chagasi plus saponin adjuvant: A new promising vaccine against visceral leishmaniasis.
    de Oliveira Emerick S; Vieira de Carvalho T; Meirelles Miranda B; Carneiro da Silva A; Viana Fialho Martins T; Licursi de Oliveira L; de Almeida Marques-da-Silva E
    Vaccine; 2021 Jan; 39(2):282-291. PubMed ID: 33309484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein.
    Fernandes AP; Costa MM; Coelho EA; Michalick MS; de Freitas E; Melo MN; Luiz Tafuri W; Resende Dde M; Hermont V; Abrantes Cde F; Gazzinelli RT
    Vaccine; 2008 Oct; 26(46):5888-95. PubMed ID: 18786587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.
    Shahbazi M; Zahedifard F; Taheri T; Taslimi Y; Jamshidi S; Shirian S; Mahdavi N; Hassankhani M; Daneshbod Y; Zarkesh-Esfahani SH; Papadopoulou B; Rafati S
    PLoS One; 2015; 10(7):e0132794. PubMed ID: 26197085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.